The impact of Clostridium butyricum MIYAIRI 588 on the murine gut microbiome and colonic tissue
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND Clostridium butyricum MIYAIRI 588 (CBM 588) is a probiotic bacterium that is used as an anti-diarrheal medicine in Japan. However, the impact of this probiotic on the gut microbiome has not been fully elucidated, especially, when used with antimicrobials. MATERIAL AND METHODS In an in vivo study, CBM 588 monotherapy, clindamycin monotherapy, CBM 588 and clindamycin (combination therapy), or normal saline (control) was orally administered to mice for 4 days, and fecal samples were collected for 18 days to enumerate C. butyricum. We also extracted DNA from these fecal samples for metagenomics analysis by amplification of the V3-V4 region of the bacterial 16S rRNA gene and MiSeq Illumina sequencing. In addition, the concentrations of some short chain fatty acids were assessed in the fecal samples. A histological analysis was also conducted. RESULTS On day 4 (the last treatment day), there was no difference in the total counts of C. butyricum between the CBM 588 monotherapy and combination therapy groups (5.21 ± 0.78 vs. 5.13 ± 0.45 log10 cfu/g, p = 0.86). Clindamycin treatment resulted in dramatic increases in the phylum Firmicutes, especially Enterobacteriaceae, Clostridiaceae, Lactobacillus, and Enterococcus, compared with the other groups during the treatment period. CBM 588 treatment modified the bacterial community composition at lower phylogenetic levels. Some bacterial taxa, such as Bifidobacterium, Coprococcus, and Bacteroides, were significantly increased in the combination therapy group when compared with the other groups. In the metabolic analysis, CBM 588 enhanced lactic acid production. It also enhanced the efficiency of lactic acid use for the production of butyric acid. Only the clindamycin monotherapy group showed abnormal colon tissue, with superficial epithelial necrosis and the presence of inflammatory cells. CONCLUSION CBM 588 treatment modulated the gut microbiota composition under dysbiosis due to the use of an antimicrobial with strong activity against anaerobes and significantly reduced epithelial damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Topping, D. L., & Clifton, P. M. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1031 · Cited by 3,091
The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria
Johansson, M. E. V., Phillipson, M., Petersson, J., Velcich, A., Holm, L., & Hansson, G. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803124105 · Cited by 2,200
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Kostic, A. D., Xavier, R. J., & Gevers, D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.009 · Cited by 1,789
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia
Bartlett, J. G., Chang, T. W., Gurwith, M., Gorbach, S. L., & Onderdonk, A. B. (1978) · New England Journal of Medicine · doi:10.1056/nejm197803092981003 · Cited by 1,374
Brown, C. T., Davis-Richardson, A. G., Giongo, A., Gano, K. A., Crabb, D. B., Mukherjee, N., Casella, G., Drew, J. C., Ilonen, J., Knip, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025792 · Cited by 778
Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases
Peterson, D. A., Frank, D. N., Pace, N. R., & Gordon, J. I. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.05.001 · Cited by 503
Intestinal Microbes in Inflammatory Bowel Diseases
Sartor, R. B., & Mazmanian, S. K. (2012) · The American Journal of Gastroenterology Supplements · doi:10.1038/ajgsup.2012.4 · Cited by 206
Cited by
Butyrate-producing human gut symbiont, Clostridium butyricum , and its role in health and disease
Stoeva, M. K., Garcia-So, J., Justice, N., Myers, J., Tyagi, S., Nemchek, M., McMurdie, P. J., Kolterman, O., & Eid, J. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1907272 · Cited by 518
Tomita, Y., Ikeda, T., Sakata, S., Saruwatari, K., Sato, R., Iyama, S., Jodai, T., Akaike, K., Ishizuka, S., Saeki, S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0051 · Cited by 256
Salgia, N. J., Bergerot, P. G., Maia, M. C., Dizman, N., Hsu, J., Gillece, J. D., Folkerts, M., Reining, L., Trent, J., Highlander, S. K., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.07.011 · Cited by 194
Hagihara, M., Kuroki, Y., Ariyoshi, T., Higashi, S., Fukuda, K., Yamashita, R., Matsumoto, A., Mori, T., Mimura, K., Yamaguchi, N., et al. (2020) · iScience · doi:10.1016/j.isci.2019.100772 · Cited by 162
Self-citationAriyoshi, T., Hagihara, M., Eguchi, S., Fukuda, A., Iwasaki, K., Oka, K., Takahashi, M., Yamagishi, Y., & Mikamo, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.587725 · Cited by 45
Self-citation
Metadata
- Authors
- Hagihara, M., Yamashita, R., Matsumoto, A., Mori, T., Kuroki, Y., Kudo, H., Oka, K., Takahashi, M., Nonogaki, T., Yamagishi, Y., & Mikamo, H.
- Venue
- Anaerobe
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 54
- Pages
- 8-18
- ISSN
- 1075-9964 (ISSN-L)
- OpenAlex
- W2887627155
- Cited by
- 60
- References
- 7
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The impact of Clostridium butyricum MIYAIRI 588 on the murine gut microbiome and colonic tissue. https://app.cochat.ai/papers/10.1016/j.anaerobe.2018.07.012
- The paper
- Hagihara, M., Yamashita, R., Matsumoto, A., Mori, T., Kuroki, Y., Kudo, H., Oka, K., Takahashi, M., Nonogaki, T., Yamagishi, Y., & Mikamo, H. (2018). The impact of Clostridium butyricum MIYAIRI 588 on the murine gut microbiome and colonic tissue. Anaerobe. https://doi.org/10.1016/j.anaerobe.2018.07.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.